Tzield (teplizumab-mzwv) Coverage Criteria
Customize your policy alerts
Sign up for Molina Healthcare Policy C24729-A alerts
Get alerted when Policy C24729-A changes without checking for updates manually.
Monitor payer policy activity
This policy governs Molina Healthcare coverage and prior authorization for intravenous Tzield in members with Stage 2 or recently diagnosed Stage 3 type 1 diabetes. Coverage requires diagnosis-specific clinical documentation, age eligibility, endocrinology prescribing or consultation, and administration in a non-hospital facility-based setting.
The Q3 2026 revision history identifies updates to required medical information, age restrictions, FDA-approved uses, the appendix, background, contraindications/exclusions/discontinuation, other special considerations, and references.
The Q2 2026 revision history identifies updates to required medical information and place-of-administration content.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.